Serum levels of soluble interleukin-2 receptor in patients with primary nephrotic syndrome. 1998

M D Ayli, and N Duman, and M Duranay, and K Ateş, and M Ayli, and O Karatan, and B Erbay, and E Ertuğ

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009404 Nephrotic Syndrome A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction. Childhood Idiopathic Nephrotic Syndrome,Frequently Relapsing Nephrotic Syndrome,Multi-Drug Resistant Nephrotic Syndrome,Pediatric Idiopathic Nephrotic Syndrome,Steroid-Dependent Nephrotic Syndrome,Steroid-Resistant Nephrotic Syndrome,Steroid-Sensitive Nephrotic Syndrome,Multi Drug Resistant Nephrotic Syndrome,Nephrotic Syndrome, Steroid-Dependent,Nephrotic Syndrome, Steroid-Resistant,Nephrotic Syndrome, Steroid-Sensitive,Nephrotic Syndromes,Steroid Dependent Nephrotic Syndrome,Steroid Resistant Nephrotic Syndrome,Steroid Sensitive Nephrotic Syndrome,Steroid-Dependent Nephrotic Syndromes,Steroid-Resistant Nephrotic Syndromes,Steroid-Sensitive Nephrotic Syndromes,Syndrome, Nephrotic,Syndrome, Steroid-Sensitive Nephrotic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015375 Receptors, Interleukin-2 Receptors present on activated T-LYMPHOCYTES and B-LYMPHOCYTES that are specific for INTERLEUKIN-2 and play an important role in LYMPHOCYTE ACTIVATION. They are heterotrimeric proteins consisting of the INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT, the INTERLEUKIN-2 RECEPTOR BETA SUBUNIT, and the INTERLEUKIN RECEPTOR COMMON GAMMA-CHAIN. IL-2 Receptors,Interleukin-2 Receptor,Interleukin-2 Receptors,Receptors, IL-2,Receptors, T-Cell Growth Factor,T-Cell Growth Factor Receptors,IL-2 Receptor,IL2 Receptor,IL2 Receptors,Interleukin 2 Receptor,Receptor, TCGF,T-Cell Growth Factor Receptor,TCGF Receptor,TCGF Receptors,IL 2 Receptor,IL 2 Receptors,Interleukin 2 Receptors,Receptor, IL-2,Receptor, IL2,Receptor, Interleukin 2,Receptor, Interleukin-2,Receptors, IL 2,Receptors, IL2,Receptors, Interleukin 2,Receptors, T Cell Growth Factor,Receptors, TCGF,T Cell Growth Factor Receptor,T Cell Growth Factor Receptors
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune

Related Publications

M D Ayli, and N Duman, and M Duranay, and K Ateş, and M Ayli, and O Karatan, and B Erbay, and E Ertuğ
October 1993, Pediatric nephrology (Berlin, Germany),
M D Ayli, and N Duman, and M Duranay, and K Ateş, and M Ayli, and O Karatan, and B Erbay, and E Ertuğ
May 1991, Nihon Jinzo Gakkai shi,
M D Ayli, and N Duman, and M Duranay, and K Ateş, and M Ayli, and O Karatan, and B Erbay, and E Ertuğ
July 1987, Clinical and experimental immunology,
M D Ayli, and N Duman, and M Duranay, and K Ateş, and M Ayli, and O Karatan, and B Erbay, and E Ertuğ
March 1997, Breast cancer (Tokyo, Japan),
M D Ayli, and N Duman, and M Duranay, and K Ateş, and M Ayli, and O Karatan, and B Erbay, and E Ertuğ
January 1995, The Journal of asthma : official journal of the Association for the Care of Asthma,
M D Ayli, and N Duman, and M Duranay, and K Ateş, and M Ayli, and O Karatan, and B Erbay, and E Ertuğ
April 1998, Anales de medicina interna (Madrid, Spain : 1984),
M D Ayli, and N Duman, and M Duranay, and K Ateş, and M Ayli, and O Karatan, and B Erbay, and E Ertuğ
August 1993, Arerugi = [Allergy],
M D Ayli, and N Duman, and M Duranay, and K Ateş, and M Ayli, and O Karatan, and B Erbay, and E Ertuğ
April 1999, Archives of oral biology,
M D Ayli, and N Duman, and M Duranay, and K Ateş, and M Ayli, and O Karatan, and B Erbay, and E Ertuğ
January 1996, Hepato-gastroenterology,
M D Ayli, and N Duman, and M Duranay, and K Ateş, and M Ayli, and O Karatan, and B Erbay, and E Ertuğ
August 1991, Neurology,
Copied contents to your clipboard!